Guizhou Yibai Pharmaceutical Co., Ltd. (SHA:600594)
China · Delayed Price · Currency is CNY 4.060
+0.040 (1.00%)
Feb 4, 2026, 3:00 PM CST
SHA:600594 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,883 | 2,150 | 2,808 | 2,729 | 3,343 | 3,405 |
Other Revenue | 23.87 | 23.87 | 12.45 | 5.98 | 3.87 | 8.01 |
| 1,907 | 2,174 | 2,821 | 2,735 | 3,347 | 3,413 | |
Revenue Growth (YoY) | -20.46% | -22.92% | 3.12% | -18.27% | -1.95% | 1.55% |
Cost of Revenue | 778.18 | 852.07 | 935.74 | 814.48 | 747.9 | 715.91 |
Gross Profit | 1,129 | 1,322 | 1,885 | 1,921 | 2,599 | 2,697 |
Selling, General & Admin | 1,209 | 1,453 | 1,590 | 1,533 | 1,979 | 2,042 |
Research & Development | 83.75 | 100.5 | 112.15 | 126.93 | 136.07 | 146 |
Other Operating Expenses | 30.07 | 31.96 | 42.66 | 11.62 | 43.16 | 41.52 |
Operating Expenses | 1,318 | 1,581 | 1,741 | 1,671 | 2,166 | 2,231 |
Operating Income | -189.47 | -258.95 | 143.79 | 249.46 | 433.12 | 466.66 |
Interest Expense | -22.54 | -26.39 | -21.64 | -37.48 | -35.13 | -41.27 |
Interest & Investment Income | 4.3 | 7.37 | 7.1 | 7.32 | 42.1 | 11.36 |
Other Non Operating Income (Expenses) | 9.13 | -0.4 | -5.55 | -14.82 | -10.58 | -2.19 |
EBT Excluding Unusual Items | -198.57 | -278.37 | 123.7 | 204.48 | 429.5 | 434.57 |
Impairment of Goodwill | -32.78 | -32.78 | - | -613.62 | -138.4 | -140.72 |
Gain (Loss) on Sale of Investments | -0.36 | - | - | -0.17 | - | -4.23 |
Gain (Loss) on Sale of Assets | -21.35 | -0.96 | -0.51 | 27.21 | -2.93 | 1.83 |
Asset Writedown | 0.91 | -23.5 | -19.4 | -9.97 | -2.24 | -11.93 |
Other Unusual Items | 0.38 | 3.09 | 28.53 | - | 24.42 | 17.95 |
Pretax Income | -251.77 | -332.52 | 132.32 | -392.07 | 310.37 | 297.47 |
Income Tax Expense | -0.71 | 2.15 | 40.96 | 46.19 | 79.57 | 86.13 |
Earnings From Continuing Operations | -251.06 | -334.67 | 91.36 | -438.26 | 230.79 | 211.34 |
Minority Interest in Earnings | 16.44 | 17.46 | 12.04 | 11.87 | 12.98 | 17.42 |
Net Income | -234.63 | -317.22 | 103.4 | -426.39 | 243.77 | 228.76 |
Net Income to Common | -234.63 | -317.22 | 103.4 | -426.39 | 243.77 | 228.76 |
Net Income Growth | - | - | - | - | 6.56% | 61.22% |
Shares Outstanding (Basic) | 786 | 789 | 789 | 793 | 791 | 792 |
Shares Outstanding (Diluted) | 786 | 789 | 789 | 793 | 791 | 792 |
Shares Change (YoY) | -0.39% | -0.03% | -0.41% | 0.14% | -0.01% | -0.15% |
EPS (Basic) | -0.30 | -0.40 | 0.13 | -0.54 | 0.31 | 0.29 |
EPS (Diluted) | -0.30 | -0.40 | 0.13 | -0.54 | 0.31 | 0.29 |
EPS Growth | - | - | - | - | 6.57% | 61.45% |
Free Cash Flow | 42.37 | -9.45 | 247.23 | 22.38 | 486.43 | -29.08 |
Free Cash Flow Per Share | 0.05 | -0.01 | 0.31 | 0.03 | 0.61 | -0.04 |
Dividend Per Share | - | - | 0.066 | - | - | 0.430 |
Dividend Growth | - | - | - | - | - | 43.33% |
Gross Margin | 59.19% | 60.81% | 66.82% | 70.22% | 77.65% | 79.03% |
Operating Margin | -9.94% | -11.91% | 5.10% | 9.12% | 12.94% | 13.67% |
Profit Margin | -12.30% | -14.59% | 3.67% | -15.59% | 7.28% | 6.70% |
Free Cash Flow Margin | 2.22% | -0.43% | 8.77% | 0.82% | 14.54% | -0.85% |
EBITDA | -11.36 | -75.06 | 335.4 | 421.45 | 580.68 | 607.56 |
EBITDA Margin | -0.60% | -3.45% | 11.89% | 15.41% | 17.35% | 17.80% |
D&A For EBITDA | 178.11 | 183.9 | 191.61 | 171.99 | 147.56 | 140.9 |
EBIT | -189.47 | -258.95 | 143.79 | 249.46 | 433.12 | 466.66 |
EBIT Margin | -9.94% | -11.91% | 5.10% | 9.12% | 12.94% | 13.67% |
Effective Tax Rate | - | - | 30.96% | - | 25.64% | 28.95% |
Revenue as Reported | 1,907 | 2,174 | 2,821 | 2,735 | 3,347 | 3,413 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.